First, BRAF-mutant colorectal cancer has significantly worse prognosis than does disease with wild-type KRAS and NRAS. 13Second, despite some conflicting evidence, BRAF-mutant tumours gain no additional benefit from targeted EGFR inhibition.14 This evidence concerns the gene KRAS and neoplasm.